Training Example: Roche (Roche Group) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

[H2] Doing now what patients need next
Pioneering diagnostics and pharma to create a healthier future for everyoneRead our storyAbout Roche
[IMG: A family gathers around an outdoor table, enjoying a meal. A man hugs a smiling boy, while two women sit nearby, all appearing content and joyful.]
[H2] In the spotlight
Roche publishes its first quarter results for 2026 Roche reports 7% (CER) sales for the full year results in 2025. Commenting on the results, CEO Thomas Schinecker said: “2025 was a strong year for Roche, reflecting our continued focus on operational and R&D excellence.” How we improved outcomes for patients around the world With our combined strengths in Diagnostic and Pharmaceuticals, we worked to provide real and positive change for patients, the people they love and the professionals who care for them. Discover the highlights in our Annual Report.Visit Media centerOur two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.
[IMG: Portrait of Thomas Schinecker]
Dr Thomas SchineckerCEO Roche Group
[H2] Investor information
Visit Investor centerMarket Cap
[H3] CHF 225B
Finance Information ToolDividend Yield
[H3] 3.2%
Share and Bond InformationNext Report
[H3] 23 July 2026
Reporting
[H2] We are Roche
We combine life-changing diagnostics and medicines to take on the toughest healthcare challenges, those that place the greatest strain on patients, families, communities, and health systems. Guided by the experiences of patients, we are determined to prevent, stop and cure diseases so people can live healthier, longer lives.
[IMG: Man holding a surfing board smiling with a ocean in the background.]
[H2] Our mission in action
[IMG: Two colleagues sit on a green couch in a modern office, engaged in conversation. One person gestures while speaking, and the other listens attentively with a slight smile.]
Prevent
[H3] Identifying high-risk patients
We prevent diseases by identifying high-risk patients early to enable timely use of medicines.Our strategy
[IMG: A laboratory scientist wearing safety glasses and gloves looks into a microscope while conducting research in a lab setting.]
Stop
[H3] Halting disease progression
We stop disease progression by accurately diagnosing patients and delivering targeted medicines.Our diagnostics solutions
[IMG: A laboratory professional wearing glasses and gloves explains a piece of equipment to a colleague while holding its open lid in a lab setting.]
Cure
[H3] Restoring health through medicines
We prevent diseases by identifying high-risk patients early to enable timely use of medicines.Our pharma solutions
[H2] Read our stories
View all stories
[IMG: Illustration of an outstretched hand cradling a large red blood drop, surrounded by floating red blood cells, set against a soft peach background.]
[H3] Raising the bar in haemophilia A care
Discover how Dr. John Pasi from Roche envisions the future of haemophilia A care, driven by innovation, personalisation, and a commitment to meeting the evolving needs of people worldwide.Read the story
[IMG: Male scientist in a lab, wearing safety glasses and gloves, examining a sample near stacked trays. The scene is lit with a clinical, blue hue.]
[H3] AI and machine learning: Revolutionising drug discovery and transforming patient careInnovation
Our Basel team is pioneering machine learning approaches that are cutting drug discovery time in half
[IMG: Bird]
[H3] SBTi validates Roche’s net-zero targetsSustainability
The Science-Based Targets initiative’s validation of our net-zero targets is a major milestone in the next phase of our action on climate change.
[H2] Shape the future of healthcare
Join our global team of innovators, scientists, and changemakersExplore CareersInclusion and Belonging at Roche
[IMG: A gloved hand holds a petri dish with gold-colored bacterial colonies on a reddish-brown medium, suggesting a laboratory experiment.]
[H3] About Roche
We unite leading science and technology across diagnostics, medicines, and digital solutions to prevent, stop and cure diseases.
[IMG: Abstract close-up of geometric shapes with vibrant pink and orange hues. A pattern of glowing circles creates an energetic and modern feel.]
[H3] Solutions
We are committed to tackling the most complex healthcare challenges that place the greatest strain on people and societies worldwide.
[IMG: 3D Insights into Novel Cancer Models.]
[H3] Innovation
In everything we do, we are guided by the needs of patients and their loved ones, acting with integrity, courage and passion.
[IMG: Close-up of a microplate with multiple wells, each being filled by thin metallic pipettes. The setting is a laboratory environment, conveying precision.]
[H3] Media
Access a wide range of materials relating to our company, our people, innovation, solutions and diagnostics tools or get in touch with us.
[IMG: Modern indoor space with large windows, wooden walls, and hanging lights. Curved planter with lush green ferns and plants creates a refreshing atmosphere.]
[H3] Investors
We are committed to delivering value for all our stakeholders through continuous innovation, groundbreaking solutions, trust and sustainable business practices.

[H1] About Roche
Since our founding over 125 years ago, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. Our commitment to our people, partners, stakeholders and, most importantly, our patients remains as strong as it was on the first day of our journey.Zur deutschen Version
[H2] Roche at a glance
[H2] 100 000 +
collaborators worldwide
[H2] 125 +
years of innovation
[H2] 39 million
patients treated with our medicines in 2025Roche is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. The company was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 100 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focused on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
[H4] Transcript
Making a real difference to people's health.That's what drives us.We're not here to do what's easy.We work to provide real and positive change for patients, the people they love, and the professionals who care for them.For generations, we have dedicated ourselves to tackling healthcare challenges where our impact matters most.Our focus is on areas like oncology, neurology, and cardiovascular and metabolic diseases.Conditions like these place the greatest strain on patients, families, communities, and healthcare systems around the world.Detecting diseases earlier and understanding them better means we can provide patients with the right treatments quicker.This is how our life-changing diagnostics and medicines help people live healthier, longer lives.And we are persistent. We keep going even in the toughest areas of research, and we learn from the experiences of those living with disease every day.Because of all of this, we are finding new ways to make a difference.From developing tests to diagnose conditions like neurological disorders and cancers before symptoms occur, to delivering first-of-their-kind medicines that halt and even reverse diseases in areas from autoimmunity to metabolic health.We are also making treatments more accessible and available closer to patients’ homes.We are determined to prevent, stop and cure diseases. Not someday, but now.Because every medical breakthrough means more birthdays, more experiences, more moments with those who matter most.We are doing now what patients needs next.
[H3] Our business
Our leading science and technology, combined with the strength of our Diagnostics and Pharmaceuticals divisions enables us to positively impact patients, families, communities and healthcare systems worldwide.
[H3] Our strategy
Keeping patients at the heart of everything we do, our ambition is clear: to prevent, stop, and cure diseases, improving outcomes and reducing costs for patients and healthcare systems worldwide.
[H3] Meet our leadership team
Our leadership influences every aspect of the company. It is committed to our long-term ambitions while ensuring we address the needs of our people.
[H2] Governance
Our corporate governance principles focus on sustainable value creation and promote a culture that recognises standards of good corporate governance and a commitment to transparent communication.Read more
[IMG: A close-up shot of wooden chairs.]
Creating sustainable impact means acting responsibly, expanding access to healthcare and contributing to the communities in which we operate.
[IMG: Two people walk and converse in a modern, bright hallway with large white panels and glass railings, creating an open and professional atmosphere.]
[H3] Roche Global Citizenship
Through our philanthropic collaborations, we empower resilient and healthy communities where we live, work, and beyondRead more
[IMG: A child in a red and white dress colors at a small table with paper and markers, guided by an adult next to her. A smiling woman watches in the background.]
[H3] Sustainability at Roche
At Roche, sustainability means operating with a long-term mindset – ensuring more people can benefit from our science and innovation today without compromising the world they will live in tomorrow.Read more
[IMG: A woman smiling warmly at the camera.]
[H3] Inclusion and Belonging at Roche
At Roche, we do our best work when everyone can realise their full potential and feel they belong—united by our shared purpose to improve patients' lives.Read more
[H2] Our history
Roche was founded in Basel, Switzerland in 1896 as one of the first manufacturers of branded medicines. Today, we are the world’s largest biotechnology company and the global leader in in-vitro diagnostics.Read more
[IMG: A vintage 1920s analytical laboratory with equipment and glassware.]
[H2] We are Roche
See all stories
[H5] Möchten Sie den Inhalt auf Deutsch lesen?
Zur deutschen Version

[H1] Investors
[H2] Roche Diagnostics Day 2026
Roche has hosted a Diagnostics Day on Tuesday, 12th May 2026 in London. Please click here to watch the replay Presentation download
[IMG: Decorative illustration]
[H2] Roche’s Investor Event at ASCO 2026
Tuesday, 2 June 2026 at 2:00PM CDT - Chicago More details
[IMG: Panoramic view of a city skyline against a clear sky, with tall skyscrapers outlined in sunlight, and a calm body of water in the foreground.]
[H2] Roche’s First Quarter Sales 2026 Presentation
Roche has published its First Quarter Sales for 2026 prior to the opening of the Swiss Stock Exchange on Thursday, 23rd April 2026. Please click here to watch the replay Presentation download Presentation with appendix
[IMG: A blue-gloved hand delicately holds a small pink container with a QR code. Nearby are green, blue, and yellow containers on a white surface, indicating a scientific setting.]
[H2] Investors at a glance
[H2] +11%
Core earnings per share growth at Constant Exchange Rates in 2025 (Core EPS 19.46 CHF - diluted)
[H2] 39 million
patients were treated with Roche medicines in 2025
[H2] 31 billion
Roche Diagnostic tests were delivered to customers worldwide in 2025Product Development PipelineRead the letter to shareholdersOur two divisions are focusing jointly on three disease areas that will account for almost 50% of the global disease burden by 2035: cancer, cardiovascular-metabolic diseases and neurological diseases.
[IMG: Portrait of Thomas Schinecker]
Dr Thomas SchineckerCEO Roche Group
[H2] Investor updates
View all updatesView ad-hoc announcementsSubscribe
[H2] Upcoming Investor events
View all events
[H3] Deutsche Bank Access European Champions ConferenceInvestors
May 26, 2026 at 08:00 CEST | Frankfurt, DERead moreAdd to calendar
[H3] Bernstein 20th Annual Strategic Decisions ConferenceInvestors
May 27, 2026 at 08:00 EDT | New York, USRead moreAdd to calendar
[H3] Roche’s Investor Event at ASCO 2026Investors
June 02, 2026 at 14:00 CDT | Chicago, USRead moreAdd to calendar
[H3] Jefferies Global Life Science ConferenceInvestors
June 03, 2026 at 08:00 EDT | New York, USRead moreAdd to calendar
[H3] BNP Paribas Exane 28th CEO ConferenceInvestors
June 04, 2026 at 08:00 CEST | Paris, FRRead moreAdd to calendar
[H3] Goldman Sachs 28th Annual Global Healthcare ConferenceInvestors
June 08, 2026 at 08:00 EST | Miami, USRead moreAdd to calendar
[H3] Roche’s Virtual ADA Investor EventInvestors
June 08, 2026 at 17:00 CESTRead moreAdd to calendar
[H3] Citi European Healthcare ConferenceInvestors
June 11, 2026 at 08:00 BST | London, UK
Read moreAdd to calendar
[H3] J.P. Morgan European Healthcare ForumInvestors
June 18, 2026 at 08:00 EST | London, UKRead moreAdd to calendar
[H2] Latest reports
[IMG: decorative image]
[H3] Annual report 2025Investors
[IMG: Smiling scientist in a lab coat and safety glasses holds a pipette in a modern laboratory. The setting conveys focus and innovation.]
[H3] Half-year report 2025Investors
[H3] Finance Information Tool
[H3] Reporting
[H3] Download center
[H3] Share and Bond information
[H3] US investors
[H3] ESG Index
[H3] Investor relations team contacts
Do you need to get in touch with us? Reach out to our investor relations team with your enquiries.View investor contact detail
[H2] Discover More
[H3] Roche Diagnostics news
Follow the most recent updates from our Diagnostics business
[H3] Genentech
Genentech has been delivering on the promise of biotechnology for over 35 years.
[H3] Sustainability at RocheAbout Roche
At Roche, sustainability means operating with a long-term mindset – ensuring more people can benefit from our science and innovation today without compromising the world they will live in tomorrow.
[H3] Positions, policies & downloadsAbout Roche
Download our policies, guidelines, positions and other documents.
[H3] Frequently asked questionsInvestors
We answer the Roche investors-related most frequently asked questions
[H3] PartneringInnovation
At Roche Partnering, we are passionate about science: yours and ours. Through partnerships, we hope that together we can build a better future with medicines that make a real difference to patients.

[H1] IR Events
loading
[H2] Investor relation team contacts
View IR team contact detail

[H1] Roche Pharma solutions
AllAnaemiaCancer (blood cancers)Cancer (solid tumours)DermatologyHaematologyInfectious DiseasesInflammatory & Autoimmune DiseasesNeurological DisordersOphthalmologyRespiratory DisordersTransplantation
[IMG: [Product] Actemra]
[H3] Actemra/RoActemra
[IMG: [Product] Alecensa]
[H3] Alecensa
[IMG: Image of avastin]
[H3] Avastin
[IMG: Image of cellcept]
[H3] CellCept
[IMG: Product image Columvi]
[H3] Columvi
[IMG: Image of Cotellic]
[H3] Cotellic
[IMG: Image of Enspryng]
[H3] Enspryng
[IMG: Image of Erivedge]
[H3] Erivedge
[IMG: Image of Esbriet]
[H3] Esbriet
[IMG: Bottle and box of Evrysdi (risdiplam) 60 mg/80 mL oral solution]
[H3] Evrysdi
[IMG: Image of Fuzeon]
[H3] Fuzeon
[IMG: Image of Gazyva]
[H3] Gazyva/Gazyvaro
[IMG: Image of Hemlibra]
[H3] Hemlibra
[IMG: Image of Herceptin]
[H3] Herceptin
[IMG: Vial of Herceptin 600 mg/5 ml (trastuzumab) solution for subcutaneous injection,]
[H3] Herceptin SC / Herceptin Hylecta
[IMG: Itobevi product picture]
[H3] Itovebi
[IMG: Vial of Kadcyla 160 mg (trastuzumab emtansine) powder for concentrate for solution for infusion]
[H3] Kadcyla
[IMG: [Product] Lunsumio]
[H3] Lunsumio
[IMG: Image of Mabthera]
[H3] MabThera / Rituxan
[IMG: Box and vial of MabThera 1600 mg (rituximab) solution for subcutaneous injection, 13.4 ml]
[H3] MabThera SC / Rituxan Hycela
[IMG: Box of Madopar 125, containing 100 mg of levodopa and 25 mg of benserazide per capsule, used as a prescription medication for treating Parkinson]
[H3] Madopar
[IMG: 208/328c4810da/mircera-tea]
[H3] Mircera
[IMG: Image of NeoRecormon]
[H3] NeoRecormon
[IMG: Image of the Ocrevus medicine box]
[H3] Ocrevus
[IMG: Product image Perjeta]
[H3] Perjeta
[IMG: Vial and box of Phesgo® 1200 mg/600 mg solution for injection (pertuzumab/trastuzumab)]
[H3] Phesgo
[IMG: Product image of Piasky]
[H3] PiaSky
[IMG: Image of Polivy]
[H3] Polivy
[IMG: Image of the Pulmozyme medicine box]
[H3] Pulmozyme
[IMG: Image of the Roaccutane medicine box]
[H3] Roaccutane/Accutane
[IMG: Image of Rocephin]
[H3] Rocephin
[IMG: Image of Rozlytrek]
[H3] Rozlytrek
[IMG: Susvimo product]
[H3] Susvimo
[IMG: Image of the Tamiflu medicine box]
[H3] Tamiflu
[IMG: Image of the Tecentriq medicine box]
[H3] Tecentriq
[IMG: Vabysmo product]
[H3] Vabysmo
[IMG: Image of Xofluza]
[H3] Xofluza
[IMG: Image of the Zelboraf medicine box]
[H3] Zelboraf
[IMG: 208/328c4810da/mircera-tea]
[H3] Mircera
[IMG: Image of NeoRecormon]
[H3] NeoRecormon
[IMG: [Product] Alecensa]
[H3] Alecensa
[IMG: Product image Columvi]
[H3] Columvi
[IMG: Image of Gazyva]
[H3] Gazyva/Gazyvaro
[IMG: [Product] Lunsumio]
[H3] Lunsumio
[IMG: Image of Mabthera]
[H3] MabThera / Rituxan
[IMG: Box and vial of MabThera 1600 mg (rituximab) solution for subcutaneous injection, 13.4 ml]
[H3] MabThera SC / Rituxan Hycela
[IMG: Image of Polivy]
[H3] Polivy
[IMG: [Product] Alecensa]
[H3] Alecensa
[IMG: Image of avastin]
[H3] Avastin
[IMG: Image of Cotellic]
[H3] Cotellic
[IMG: Image of Erivedge]
[H3] Erivedge
[IMG: Image of Herceptin]
[H3] Herceptin
[IMG: Vial of Herceptin 600 mg/5 ml (trastuzumab) solution for subcutaneous injection,]
[H3] Herceptin SC / Herceptin Hylecta
[IMG: Itobevi product picture]
[H3] Itovebi
[IMG: Vial of Kadcyla 160 mg (trastuzumab emtansine) powder for concentrate for solution for infusion]
[H3] Kadcyla
[IMG: Product image Perjeta]
[H3] Perjeta
[IMG: Vial and box of Phesgo® 1200 mg/600 mg solution for injection (pertuzumab/trastuzumab)]
[H3] Phesgo
[IMG: Image of Rozlytrek]
[H3] Rozlytrek
[IMG: Image of the Tecentriq medicine box]
[H3] Tecentriq
[IMG: Image of the Zelboraf medicine box]
[H3] Zelboraf
[IMG: Image of the Roaccutane medicine box]
[H3] Roaccutane/Accutane
[IMG: Image of Hemlibra]
[H3] Hemlibra
[IMG: Product image of Piasky]
[H3] PiaSky
[IMG: [Product] Actemra]
[H3] Actemra/RoActemra
[IMG: Image of Fuzeon]
[H3] Fuzeon
[IMG: Image of Rocephin]
[H3] Rocephin
[IMG: Image of the Tamiflu medicine box]
[H3] Tamiflu
[IMG: Image of Xofluza]
[H3] Xofluza
[IMG: [Product] Actemra]
[H3] Actemra/RoActemra
[IMG: Image of cellcept]
[H3] CellCept
[IMG: Image of Mabthera]
[H3] MabThera / Rituxan
[IMG: Image of Enspryng]
[H3] Enspryng
[IMG: Bottle and box of Evrysdi (risdiplam) 60 mg/80 mL oral solution]
[H3] Evrysdi
[IMG: Box of Madopar 125, containing 100 mg of levodopa and 25 mg of benserazide per capsule, used as a prescription medication for treating Parkinson]
[H3] Madopar
[IMG: Image of the Ocrevus medicine box]
[H3] Ocrevus
[IMG: Susvimo product]
[H3] Susvimo
[IMG: Vabysmo product]
[H3] Vabysmo
[IMG: Image of Esbriet]
[H3] Esbriet
[IMG: Image of the Pulmozyme medicine box]
[H3] Pulmozyme
[IMG: Image of cellcept]
[H3] CellCept
Pharma Solutions
[H2] Local safety reporting
Do you have a question about one of our medicines? Would you like to provide information about a potential side effect or raise a product quality concern?Report medicine side effects
[IMG: Decorative illustration]

[H1] Contact us
This page provides details on how to get in touch with us for different types of queries relating to our medications, diagnostic products and Roche services. Any response received from Roche does not replace the advice of a physician.Please note that medications and diagnostic products cannot be directly ordered through the points of contact referenced on this page. We also do not respond to form letters or e-mail campaigns.
[H2] Quick links
[H5] Investors
Investors team contacts
[H5] Media
Media team contacts
[H5] Careers
Job centre
[H5] Partnership & suppliers
Partnership informationPartnership team contactsSuppliers portal
[H5] Grants, donations & funds
Charitable partnershipsGrants and donations
[H5] Healthcare professionals, patients & caregivers
Clinical trialsRoche for healthcare professionalsPatients support programs
[IMG: Close-up of a lab setting: a gloved hand holds a tube while a pipette dispenses liquid into adjacent pink-capped tubes in an orange rack.]
[H3] Our strategy
Keeping patients at the heart of everything we do, our ambition is clear: to prevent, stop, and cure diseases, improving outcomes and reducing costs for patients and healthcare systems worldwide.Read more
[IMG: Scientist wearing glasses and teal protective gloves examining a sample slide in a laboratory.]
[H3] Our business
Our leading science and technology, combined with the strength of our Diagnostics and Pharmaceuticals divisions enables us to positively impact patients, families, communities and healthcare systems worldwide.Read more
[IMG: A close-up shot of wooden chairs.]
[H3] Governance
Our corporate governance principles focus on sustainable value creation and promote a culture that recognises standards of good corporate governance and a commitment to transparent communication.Read more
[IMG: A close-up of a key inserted into a wooden locker. The key has a tag reading]
[H3] Roche ethical standards
As a high-performing organisation, we strive for extraordinary results in everything we do. We are committed to scientific rigour and the highest ethical standards in research and development.Read more
[IMG: Decorative image]
[H3] Product Development Pipeline
Discover our pipeline of Pharmaceutical and Diagnostics developmentsRead more
[IMG: Roche Logo]
[H3] Privacy notice
This Privacy Notice outlines the types of personal information Roche may collect; the means by which Roche may collect, use, or share your personal information; steps Roche takes to protect your personal informRead more
[H2] Do you still have questions?
Find the right point of contact belowFrequently Asked QuestionsPharmaceuticals / ProductsDiagnostics / ProductsJob enquiry & CareersMedia & InvestorsPartnership & SuppliersGeneral company informationReport a possible pharmaceutical product side effect here .Report a possible diagnostics product malfunction here .If you would like to apply for a job or send your CV for future positions, then please visit our dedicated job search page .We are aware of fraudulent activities where individuals pose as Roche representatives. To protect yourself, please note that Official Communication Channels are only via email addresses ending in @roche.com or @gene.com. Emails from similar but non-official domains are scams. Be wary of poorly written emails or those that ask for personal information and verify that they come from @roche.com or @gene.com. Roche does not make job offers without prior interviews, nor do we ask for payments of any kind. Unsolicited job offers or requests for payment are fraudulent.For genuine opportunities, visit our careers page at careers.roche.com .Media enquiriesFor all media enquiries, including interview requests and press information, please visit our dedicated Media contacts page. Investor enquiriesFor information relating to our financial performance, shareholding or investor events, please visit our Investor contacts page.Partnering enquiriesFor partnering enquiries relating to Pharmaceuticals and Diagnostics, including collaboration opportunities, please visit our Partnering contacts page. Supplier enquiriesFor information and contact details for current and prospective suppliers, please visit our Suppliers website.This contact form is here for genuine enquiries. We’re not able to respond to sales pitches, marketing messages, or unsolicited commercial offers, so these will not receive a reply.
[H2] Contacts in your local region or country
Roche is present in over 95 countries and regions. Find your contact person.See our locations
[IMG: Roche site in Tucson, featuring modern architecture and landscaped grounds, set against a backdrop of desert terrain.]
[H5] Support Hotline for Healthcare Providers and Patients in Ukraine
Roche has established a multilingual support hotline for patients and healthcare providers in or from Ukraine. Reach out to us for assistance using the following contact details: Phone: +36 146 182 58 WhatsApp: +36 707 177 394 Email: patientcare@roche.comThe hotline is accessible from 8 am to 5 pm CET. We are dedicated to providing the appropriate information and support to everyone in need.